

# Prescriber Quick Reference Sheet: enoxaparin biosimilars and cancer-associated thrombosis

Changes to PharmaCare coverage of enoxaparin and modifying Limited Coverage criteria for cancer-associated thrombosis (CAT).

There is no switching involved since prescriptions are short-term. Thank you for supporting positive outcomes for your patients.

## Enoxaparin biosimilar listings

Originator	PharmaCare-covered biosimilars	Condition(s)
enoxaparin (Lovenox®; Lovenox® HP)	Inclunox®; Inclunox® HP Noromby®; Noromby® HP Redesca®; Redesca® HP	Prophylaxis and treatment of venous thromboembolism

Effective March 22, 2022, PharmaCare is de-listing Lovenox and listing biosimilar versions Inclunox, Noromby, and Redesca for the same indications.

Existing patients taking Lovenox will keep their PharmaCare coverage until it expires. As of March 22, only enoxaparin biosimilars will be covered for new starts or renewals of prior coverage.

### Do you have a collaborative prescribing agreement (CPA) for Lovenox?

No action is required. Your CPA will automatically adjust to remove Lovenox and replace it with the approved biosimilars. Orthopedic surgeons are eligible to register for this CPA.

This means you are exempt from submitting Special Authority requests for coverage of the biosimilars, if your patient meets criteria, as before.

Note: Special Authority requests for Lovenox will only be considered on an exceptional, case-by-case basis.



## Modified criteria for cancer-associated thrombosis (CAT)

Previous Limited Coverage criteria	Modified Limited Coverage criteria
dalteparin and tinzaparin <ul style="list-style-type: none"><li>• Second-line treatment</li><li>• Must have tried warfarin first</li></ul>	dalteparin and tinzaparin <ul style="list-style-type: none"><li>• First-line treatment</li><li>• No need to try warfarin first</li></ul>
enoxaparin not covered	Adding enoxaparin biosimilars <ul style="list-style-type: none"><li>• First-line treatment</li><li>• No need to try warfarin first</li></ul>

Effective March 22, 2022, Limited Coverage criteria will change for CAT.

Dalteparin and tinzaparin will both change to first-line treatment (from second-line), removing the requirement for patients to try warfarin first.

Enoxaparin biosimilars will also be added as covered first-line treatment options for CAT. The biosimilar listings result in costs savings for the province, which offsets the costs for modifying treatment options for CAT.

### Why is coverage changing?

Biosimilars Initiative is an evidence-informed strategy to better optimize B.C.'s public resources and expand health services in B.C. and the PharmaCare formulary. Even with the success of biosimilar adoption in B.C., originator biologics continue to represent a large portion of the annual PharmaCare budget. Further adoption of biosimilars will allow for additional reinvestment in B.C.'s healthcare system.

PharmaCare only approves coverage of biosimilars that have been proven to be as safe and effective as their originator. The Ministry of Health carefully monitors drug utilization, patient outcomes, and feedback from both patients and practitioners.